Replies to post #448297 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

...it is the same as the Cognate DCVax-L Manufacturing Services Contract

Incorrect. From the 10k:

The Agreement is structured in the same manner as the Company’s prior agreements with Cognate BioServices.

(emphasis added)

Structured in the same manner, i.e. there are differences. It is not the same. Unless you are able to provide a copy of this agreement, then your basis for your prior statements is purely speculation.

[kabunushi]

NOT. The contract you linked to is from 2014. Last I looked it is now 2022 and a contract for specials and post-approval commercial would definitely not be on the same terms as a contract limited to mfg only for a clinical trial.

Specifically, that would be as referenced in the doc you linked to as 'a Manufacturing Expansion Services Agreement'. Obviously that would be completely separate from the lease agreement and is still to be defined. NWBO has filed such agreements extensively so your claims/insinuations that they are e.g. hiding some secret agreement is way out of line though rather typical of your style.

1.2 Additional Agreements



Certain additional services relating to the DCVax-L program will be provided at NW Bio’s request under separate agreements. These include an Ancillary Services Agreement and a Manufacturing Expansion Services Agreement. The Ancillary Services will include shipping distribution and logistics services; cryopreservation and storage services; clinical support services; development and validation services; recordkeeping services, and others. The Manufacturing Expansion Services will include oversight, management and support of third party manufacturing outside the U.S.,

.